Clinical Trial Update: PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating a PARP inhibitor with a CDK4/6 inhibitor and endocrine therapy for HR+/HER2-negative metastatic breast cancer; currently activ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hr-positive Breast Cancer

Drugs mentioned

• CDK4/6 inhibitor (unspecified)
• Endocrine therapy (unspecified)
• PARP inhibitor (unspecified)

Snippet

Sponsor: Zhimin Shao | Conditions: Breast Cancer Metastatic | Phase 3 | Status: ACTIVE_NOT_RECRUITING